Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.

Participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays.

Stroke

PlayStation®VR training

Chiayi Chang Gung Memorial Hospital

Effects of PlayStation®VR on the HRQOL in Stroke Patients Undergoing Inpatient Rehabilitation

Effects of PlayStation®VR on the Health-Related Quality of Life in Stroke Patients Undergoing Inpatient Rehabilitation: a Pilot Study

Post-intervention Health-Related Quality of Life

3-month follow-up Health-Related Quality of Life

Proportion of intervention-related adverse events or SAE

Post-intervention motor impairment and function

3-month follow-up motor impairment and function

The FIM is an 18-item instrument measuring a person's level of disability in terms of burden of care in six areas including self-care, continence, mobility, transfers, communication, and cognition. Each of the 18 items is graded on a scale of 1-7 based on level of independence in that item (1 = total assistance required, 7 = complete independence). Six items (eating, grooming, bathing, dressing upper body, dressing lower body, and toileting) of self care will be scored and summed in this study.

The AMR, the ratio of arm use duration between the more and less affected arm, is detected and calculated by an accelerometer. The participants are asked to wear one accelerometer (ActiGraph wGT3x-BT, ActiGraph, LLC., Pensacola, FL, USA) on each arm for 7 hours.

Chien-Min Chen

Principal Investigator

Chang Gung Memorial Hospital

All participants are randomly allocated to study group and control group. Each participant's main study period is set as 16 days with additional follow-up time at post-intervention 3 months. Participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays. Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.

Pre-intervention, post-intervention, and 3-month follow-up HRQOL will be assessed by the Stroke Impact Scale (SIS) 3.0. Motricity Index (MI) and Fugl-Meyer Assessment (FMA), Functional Independence Measure (FIM), and arm movement ratio (AMR) will also be checked before intervention, after intervention, and at 3-month follow-up. One blinded occupational therapist will evaluate the outcomes.

Ivermectin has been reported to be a SARS-CoV-2 inhibitor. This activity is believed to be due to the dependence of many different RNA viruses on IMPα / β1 during infection. These reports suggested that the inhibitory activity of ivermectin nuclear transport may be effective against SARS-CoV-2, since they demonstrate that ivermectin has antiviral action against the clinical isolate of SARS-CoV-2 in vitro, with a single dose capable to control viral replication in 24-48 hours. in vitro

Severe Acute Respiratory Syndrome

Ventilation Pneumonitis

Ivermectin 5 MG/ML

Hospital Eurnekian

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19

Considering healing and/or reducing symptoms and severity of initial presentation

Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive care

potential need of reducing or augmenting doses

Outcome of adverse effects to one or more drugs used in the clinical trial

Personal data will remain secret. Only clinical descriptions (age, gender, co-morbidities, evolution, outcomes will be released

Hector E Carvallo

Principal investigator

Eurnekian Public Hospital

Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days

Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days

COVID-19

ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Ivermectin

Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Placebo

Stromectol. FDA Approved Package Insert 2009

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms

The subject is considered to have progressed to severe illness when one or more of the following criteria are present:
Breathing difficulty (≥30 breaths per minute);
Resting oxygen saturation ≤93%;
Severe complications such as: respiratory failure, need for mechanical ventilation, septic shock, non-respiratory organic failure.

Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.

Indigenous children aged <15 years within participating communities of the Northern Territory

throat swabs, pyoderma swabs and skin scrapings for tinea where individual consent was obtained within selected participating communities

Scabies

Impetigo

Pyoderma

Streptococcal Infections

Menzies School of Health Research

Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory

East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities

scabies/kuume

Effects of PlayStation®VR on the HRQOL in Stroke Patients Undergoing Inpatient Rehabilitation

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory

Täydellisin lääketieteellinen tietokanta tieteen tukemana